The vitamin D<sub>3</sub> hormone, 1,25(OH)<sub>2</sub>D<sub>3</sub>, regulates fibroblast growth factor 23 (FGF23) production in human skin cells
The bone hormone fibroblast growth factor 23 (FGF23) regulates renal phosphate reabsorption and the enzymatic production of active vitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>]. Therefore, FGF23 production in bone cells is closely regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub> acting via the vitamin D receptor (VDR). Skin cells can produce hydroxyvitamin D<sub>3</sub> metabolites from its precursor D<sub>3</sub> made through ultraviolet B light exposure. Interestingly, the expression of Fgf23 has been found in rodent skin, but its expression, regulation, and role in human skin are unclear. Therefore, we investigated whether hydroxyvitamin D<sub>3</sub> metabolites regulate FGF23 in human skin cells. Primary adult and neonatal epidermal keratinocytes (HEKn), melanocytes (HEMn), dermal fibroblasts (HDFn), as well as human melanoma cells, HaCaT, HaCaT VDR KO, and A431 epidermoid cells, were used to assess <i>FGF23</i> gene expression (quantitative reverse-transcription real-time PCR), cellular FGF23 protein (Western blot), or secreted FGF23 protein (ELISA) after treatment with hydroxyvitamin D<sub>3</sub> metabolites. HaCaT cells treated with recombinant FGF23 were used to explore its function in skin. Human skin cells can synthesize FGF23. Treatment with 1,25(OH)<sub>2</sub>D<sub>3</sub> significantly increased <i>FGF23</i> mRNA levels in HaCaT and HDFn cells, and moderately in HEKn cells, mediated in part by the VDR. It also moderately enhanced mRNA levels of the FGF23-processing enzyme <i>GALNT3</i> and stimulated secretion of hormonally active FGF23 from HaCaT cells. Treatment of HaCaT cells with FGF23 increased mRNA levels of the cholesterol- and vitamin D-metabolizing enzymes, <i>CYP11A1</i> and <i>CYP27A1</i>. In conclusion, human skin cells express and secrete FGF23, which is regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub> acting in part by the VDR. FGF23 affects the expression of cutaneous sterol-metabolizing enzymes.<b>NEW & NOTEWORTHY</b> This study shows for the first time the expression and secretion of the FGF23 hormone by human skin cells. In addition, we identified the active vitamin D<sub>3</sub> hormone, 1,25(OH)<sub>2</sub>D<sub>3</sub>, to be a potent regulator of dermal FGF23 expression and protein secretion, partly involving the vitamin D receptor. Furthermore, we provide initial evidence demonstrating that FGF23 upregulates the gene expression of <i>CYP11A1</i> and <i>CYP27A1</i> in keratinocytes.
Authors
- Adrian Fabisiak (ORCID: https://orcid.org/0000-0002-0627-0103)
- Gabriele I. Stangl (ORCID: https://orcid.org/0000-0001-8073-524X)
- Alisa A. Mobley (ORCID: https://orcid.org/0000-0002-0979-6987)
- Pawel Brzeminski (ORCID: https://orcid.org/0000-0002-8226-9366)
- Anna A. Brożyna (ORCID: https://orcid.org/0000-0002-3195-9965)
- Andrzej T. Slominski (ORCID: https://orcid.org/0000-0001-8963-3995)
- Franz Ewendt (ORCID: https://orcid.org/0000-0003-0604-2140)
- Tae‐Kang Kim (ORCID: https://orcid.org/0000-0003-1394-4134)
- Robert C. Tuckey (ORCID: https://orcid.org/0000-0002-5022-4729)
- Zorica Janjetović (ORCID: https://orcid.org/0000-0001-6108-2212)
- Ravichandran Senthilkumar
Institutions
- The University of Western Australia (AU)
- Luther University (KR)
- Nicolaus Copernicus University (PL)
- University of Alabama at Birmingham (US)
- Birmingham VA Medical Center (US)
- University of Warsaw (PL)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- American Journal of Physiology-Cell Physiology
- Published
- 2025-03-08
- DOI
- https://doi.org/10.1152/ajpcell.00827.2024
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Deutsche Forschungsgemeinschaft
- National Institutes of Health